Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metastasis Inhibition Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FUT6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FUT6 ECD Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View FUT6 Products |
| Gene Delivery | FUT6 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Optimized for cell-based selectin binding assays. |
View FUT6 Products |
| Benchmark Ab | Anti-FUT6 Positive Control Antibody Recombinant monoclonal antibody for assay validation. |
View FUT6 Products |
| Validator | FUT6 siRNA Set For target knockdown verification and specificity controls. |
View FUT6 Products |
| Related Target A | FUT3 Highly homologous alpha-1,3-fucosyltransferase. Crucial for off-target and selectivity profiling. |
View FUT3 Products |
| Related Target B | FUT7 Key fucosyltransferase involved in sialyl Lewis X (sLeX) synthesis. Essential for comparative pathway analysis. |
View FUT7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling across homologous FUT family members | Human FUT3, FUT5, FUT6, and FUT7 ortholog proteins available with >95% purity and verified sequences. |
| Maintaining native Golgi-like glycosylation for enzymatic assays | HEK293 mammalian expression system guarantees biologically relevant post-translational modifications. |
| Lack of reliable positive control reagents | Sequence-verified Clinical Benchmark Antibodies (Biosimilars) and validated positive control antibodies. |
| False positives in phenotype screening | Sequence-specific validated siRNA sets included for target knockdown verification. |
Live FUT6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of FUT6 (Fucosyltransferase 6) is gaining momentum as oncology research shifts toward glycan-mediated tumor microenvironment interactions and metastasis inhibition. FUT6 is a key enzyme responsible for the synthesis of sialyl Lewis X (sLeX), a carbohydrate ligand critical for E-selectin-mediated tumor cell adhesion and extravasation. The race for FUT6 therapeutics is intensifying, with major players shifting focus from traditional systemic chemotherapies to targeted small molecule inhibitors of fucosylation and glycan-targeted biologics. As first-generation glycosylation inhibitors reach the clinic, the next wave of R&D is targeting highly selective, non-toxic FUT6 inhibitors to block metastasis without disrupting systemic blood group antigen synthesis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic Institutes, Biotech Startups | Colorectal Cancer, Hepatocellular Carcinoma | Enzymatic Selectivity Assay (Need high-purity FUT3/FUT5/FUT6 panels) |
| Monoclonal Antibody / ADC | Biopharma Innovators | Advanced Solid Tumors, Metastatic Breast Cancer | Target Binding & Specificity (Need native HEK293-expressed FUT6 protein) |
| siRNA / Gene Therapy | RNA Therapeutics Specialists | Metastatic Colon Cancer | Knockdown Validation (Need validated siRNA & Lentivirus for stable lines) |